Long‐term experience of pegvisomant therapy as a treatment for acromegaly
Identifieur interne : 000A44 ( Main/Exploration ); précédent : 000A43; suivant : 000A45Long‐term experience of pegvisomant therapy as a treatment for acromegaly
Auteurs : C. E. Higham [Royaume-Uni] ; T. T. Chung [Royaume-Uni] ; J. Lawrance [Royaume-Uni] ; W. M. Drake [Royaume-Uni] ; P. J. Trainer [Royaume-Uni]Source :
- Clinical Endocrinology [ 0300-0664 ] ; 2009-07.
Abstract
Aims To evaluate the long‐term efficacy and safety of pegvisomant as a treatment for acromegaly. Design Retrospective analysis of clinical and trial data from all patients treated with pegvisomant since 1997 at two centres with common protocols. Results Fifty‐seven patients (age range 27–78 years) have been treated with pegvisomant since 1997 for up to 91 months (median 18 months). Before commencing pegvisomant, patients had an IGF‐I above the upper limit of normal (ULN) of the age‐related reference range (median 1·8 × ULN, range 1·2–4·1). Ninety‐five per cent normalized IGF‐I using a median dose of 15 mg daily (range 10 mg alternate day to 60 mg daily) with no influence of gender on dose requirement. Five patients had combination therapy with either somatostatin analogues (SSA) or cabergoline. Two patients initially controlled on 10 mg and 20 mg required dose increases (to 20 mg + 40 mg) over 24 months to reduce IGF‐I. Twenty‐seven patients stopped pegvisomant. Reasons included side‐effects [abnormal liver function tests (LFTs)] and patient choice. Two patients developed elevated liver transaminases, which normalized on stopping pegvisomant. Patients had 6–12‐monthly pituitary magnetic resonance imaging (MRI) scans. One patient had significant tumour size increase. Conclusion This long‐term experience in 57 patients indicates pegvisomant to be effective, safe and well‐tolerated. Raised transaminases occurred within the first month of therapy in two patients, and tumour growth was seen in one patient (tumour was growing prior to pegvisomant). In two patients increasing doses of pegvisomant were required to keep IGF‐I within the target range.
Url:
DOI: 10.1111/j.1365-2265.2008.03469.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term experience of pegvisomant therapy as a treatment for acromegaly</title><author><name sortKey="Higham, C E" sort="Higham, C E" uniqKey="Higham C" first="C. E." last="Higham">C. E. Higham</name></author><author><name sortKey="Chung, T T" sort="Chung, T T" uniqKey="Chung T" first="T. T." last="Chung">T. T. Chung</name></author><author><name sortKey="Lawrance, J" sort="Lawrance, J" uniqKey="Lawrance J" first="J." last="Lawrance">J. Lawrance</name></author><author><name sortKey="Drake, W M" sort="Drake, W M" uniqKey="Drake W" first="W. M." last="Drake">W. M. Drake</name></author><author><name sortKey="Trainer, P J" sort="Trainer, P J" uniqKey="Trainer P" first="P. J." last="Trainer">P. J. Trainer</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C0742112B14D34F1413C40C063E734B3F1B06522</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1111/j.1365-2265.2008.03469.x</idno><idno type="url">https://api.istex.fr/document/C0742112B14D34F1413C40C063E734B3F1B06522/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002668</idno><idno type="wicri:Area/Main/Curation">002328</idno><idno type="wicri:Area/Main/Exploration">000A44</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term experience of pegvisomant therapy as a treatment for acromegaly</title><author><name sortKey="Higham, C E" sort="Higham, C E" uniqKey="Higham C" first="C. E." last="Higham">C. E. Higham</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><wicri:orgArea>Department of Endocrinology, Christie Hospital</wicri:orgArea></affiliation></author><author><name sortKey="Chung, T T" sort="Chung, T T" uniqKey="Chung T" first="T. T." last="Chung">T. T. Chung</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Endocrinology, St Bartholomew's Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Lawrance, J" sort="Lawrance, J" uniqKey="Lawrance J" first="J." last="Lawrance">J. Lawrance</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><wicri:orgArea>Department of Endocrinology, Christie Hospital</wicri:orgArea></affiliation></author><author><name sortKey="Drake, W M" sort="Drake, W M" uniqKey="Drake W" first="W. M." last="Drake">W. M. Drake</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Endocrinology, St Bartholomew's Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Trainer, P J" sort="Trainer, P J" uniqKey="Trainer P" first="P. J." last="Trainer">P. J. Trainer</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><wicri:orgArea>Department of Endocrinology, Christie Hospital</wicri:orgArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Endocrinology</title><idno type="ISSN">0300-0664</idno><idno type="eISSN">1365-2265</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2009-07">2009-07</date><biblScope unit="volume">71</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="86">86</biblScope><biblScope unit="page" to="91">91</biblScope></imprint><idno type="ISSN">0300-0664</idno></series><idno type="istex">C0742112B14D34F1413C40C063E734B3F1B06522</idno><idno type="DOI">10.1111/j.1365-2265.2008.03469.x</idno><idno type="ArticleID">CEN3469</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0300-0664</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aims To evaluate the long‐term efficacy and safety of pegvisomant as a treatment for acromegaly. Design Retrospective analysis of clinical and trial data from all patients treated with pegvisomant since 1997 at two centres with common protocols. Results Fifty‐seven patients (age range 27–78 years) have been treated with pegvisomant since 1997 for up to 91 months (median 18 months). Before commencing pegvisomant, patients had an IGF‐I above the upper limit of normal (ULN) of the age‐related reference range (median 1·8 × ULN, range 1·2–4·1). Ninety‐five per cent normalized IGF‐I using a median dose of 15 mg daily (range 10 mg alternate day to 60 mg daily) with no influence of gender on dose requirement. Five patients had combination therapy with either somatostatin analogues (SSA) or cabergoline. Two patients initially controlled on 10 mg and 20 mg required dose increases (to 20 mg + 40 mg) over 24 months to reduce IGF‐I. Twenty‐seven patients stopped pegvisomant. Reasons included side‐effects [abnormal liver function tests (LFTs)] and patient choice. Two patients developed elevated liver transaminases, which normalized on stopping pegvisomant. Patients had 6–12‐monthly pituitary magnetic resonance imaging (MRI) scans. One patient had significant tumour size increase. Conclusion This long‐term experience in 57 patients indicates pegvisomant to be effective, safe and well‐tolerated. Raised transaminases occurred within the first month of therapy in two patients, and tumour growth was seen in one patient (tumour was growing prior to pegvisomant). In two patients increasing doses of pegvisomant were required to keep IGF‐I within the target range.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Grand Manchester</li></region><settlement><li>Londres</li><li>Manchester</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Higham, C E" sort="Higham, C E" uniqKey="Higham C" first="C. E." last="Higham">C. E. Higham</name></region><name sortKey="Chung, T T" sort="Chung, T T" uniqKey="Chung T" first="T. T." last="Chung">T. T. Chung</name><name sortKey="Drake, W M" sort="Drake, W M" uniqKey="Drake W" first="W. M." last="Drake">W. M. Drake</name><name sortKey="Lawrance, J" sort="Lawrance, J" uniqKey="Lawrance J" first="J." last="Lawrance">J. Lawrance</name><name sortKey="Trainer, P J" sort="Trainer, P J" uniqKey="Trainer P" first="P. J." last="Trainer">P. J. Trainer</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A44 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A44 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C0742112B14D34F1413C40C063E734B3F1B06522
|texte= Long‐term experience of pegvisomant therapy as a treatment for acromegaly
}}
| This area was generated with Dilib version V0.6.23. |  |